TumorNext-Lynch

When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.

Downloads

Quick Reference
Test Code 8980
Turnaround Time (TAT) 3-4 weeks
Number of Genes 8
Specimen Requirements Click here

Ordering Options

Why Is This Important?

  1. Get more complete information to guide healthcare decisions with one test to rule out or confirm Lynch syndrome
  2. Know if your patient is at an increased risk for other cancers, so you can modify screening and prevention recommendations 
  3. Guide treatment decisions based on BRAF/KRAS/NRAS mutation status
  4. Guide treatment options for PD-L1/PD-1 immunotherapy based on MMR deficiency status 

When To Consider Testing

  • Patients with colorectal or endometrial cancer who are suspicious for Lynch syndrome due to abnormal MSI/IHC
  • Patients with abnormal MSI and/or IHC results, with no germline Lynch syndrome gene mutations found

Test Description

  • Tumor and germline paired analysis of MLH1, MSH2, MSH6, PMS2, and EPCAM
  • Microsatellite instability (MSI)
  • MLH1 promoter hypermethylation analysis.
  • Option to add on BRAF (V600E), NRAS, and KRAS targeted analysis
View Full Menu

Search Results

Start your search...